Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAX 3 in advanced oesophago-gastric cancer
ACTRN12609000109202Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Apr 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of panitumumab, docetaxel, cisplatin, fluorouracil and capecitabine in oesophago-gastric cancer (2 arms), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Objective response rate. Started Apr 2010; status: completed.
02
Drugs
panitumumabdocetaxelcisplatinfluorouracilcapecitabine
03
Conditions
oesophago-gastric cancer
Beyond the preview
Go deeper on ACTRN12609000109202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000109202.